Cargando…

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial

INTRODUCTION: The systemic therapy, especially androgen deprivation therapy (ADT), is currently recommended for patients with oligometastatic prostate cancer (PCa). However, the results have not been satisfactory including adverse reactions and castration resistance. Therefore, it is necessary to ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xianzhi, Wang, Tao, Ye, Yusheng, Li, Jing, Gao, Xu, Zhang, Huojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528669/ https://www.ncbi.nlm.nih.gov/pubmed/36180115 http://dx.doi.org/10.1136/bmjopen-2021-051371

Ejemplares similares

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments
por: Navarria, Pierina, et al.
Publicado: (2014)

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
por: Yeung, Rosanna, et al.
Publicado: (2017)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China
por: Zhao, Xianzhi, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
por: Wegner, Rodney E., et al.
Publicado: (2019)

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
por: Xu, Chenyang, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis
por: Katz, Alan
Publicado: (2017)

Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer
por: White, I D, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Biologically effective doses of 60–70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
por: Ye, Yusheng, et al.
Publicado: (2022)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers
por: Facondo, Giuseppe, et al.
Publicado: (2023)

Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol
por: Siltari, Aino, et al.
Publicado: (2022)

Implementation of advanced radiotherapy techniques: stereotactic body radiotherapy (SBRT) for oligometastatic patients with lung metastasis - a single institution experience
por: Pop, Dan Dumitru, et al.
Publicado: (2022)

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer
por: Boyd, Kathleen A, et al.
Publicado: (2015)

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
por: Gerum, Sabine, et al.
Publicado: (2018)

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
por: Reshko, Leonid B., et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry
por: Davis, Joanne, et al.
Publicado: (2015)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Editorial: Clinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate
por: Vargo, John A., et al.
Publicado: (2015)

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
por: Chiang, I-Ni, et al.
Publicado: (2017)

Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial
por: Xiao, Yu-Tian, et al.
Publicado: (2020)

Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study
por: Wu, Fang-Jen, et al.
Publicado: (2020)

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
por: Zhu, Xiaofei, et al.
Publicado: (2022)

The impact of hegemonic masculine ideals on self‐esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT‐naïve patients
por: Gentili, Caterina, et al.
Publicado: (2022)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Liede, Alexander, et al.
Publicado: (2016)

Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
por: Nikitas, John, et al.
Publicado: (2019)

Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol
por: Østergren, Peter, et al.
Publicado: (2016)

Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer
por: Xu, Bichun, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma
por: Mahadevan, Anand, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ed5np3a6hkmfal767dc4up1rvs